Recombinant lactoferrin - Meristem Therapeutics
Latest Information Update: 04 Feb 2011
At a glance
- Originator Meristem Therapeutics
- Class Anti-inflammatories; Antibacterials; Antidiarrhoeals; Antineoplastics; Glycoproteins; Iron binding proteins; Recombinant proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 24 Aug 2005 Phase-I clinical trials in Dry eyes in Europe (unspecified route)